^(125)I粒子植入辅助治疗晚期肝癌后IL-33、ST2、Th1/Th2相关细胞因子的变化  

Study on the changes of IL-33,ST2,Th1/Th2 after^(125)I seed implantation in adjuvant treatment of advanced liver cancer

作　　者：孙川 李宾[1] 李磊[2] SUN Chuan;LI Bin;LI Lei(Ninth Radiochemistry Department,Tangshan People's Hospital(Tangshan Hebei,063000),China;不详)

机构地区：[1]唐山市人民医院放化九科,河北唐山063000 [2]唐山市人民医院肝胆外科

出　　处：《中西医结合肝病杂志》2023年第4期311-314,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：河北省医学科学研究课题计划(No.20190123)。

摘　　要：目的:探究^(125)I粒子植入辅助治疗晚期肝癌后白细胞介素-33(IL-33)、癌性抑制基因2(ST2)、辅助性T细胞1(Th1)/辅助性T细胞2(Th2)相关细胞因子的变化。方法:选取2019年7月至2021年4月收治的94例晚期肝癌患者作为研究对象,按照随机数字表法按1∶1比例分为观察组、对照组,各47例。对照组患者采用肝动脉化学治疗栓塞术(TACE)治疗,观察组患者在对照组治疗基础上加用^(125)I粒子植入辅助治疗。比较两组患者临床疗效,治疗前、治疗后2个月肿瘤标志物水平[糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)、癌胚抗原(CEA)、α-L-岩藻糖苷酶(AFU)]、生活质量核心量表(QLQ-C30)评分、Th1[肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)]、Th2[白细胞介素-4(IL-4)、白细胞介素-6(IL-6)]相关细胞因子水平,血清IL-33、ST2水平及并发症发生率。结果:观察组患者疾病控制率74.47%高于对照组的51.06%(P<0.05);治疗后2个月,观察组患者血清CA19-9、AFP、CEA、AFU水平、QLQ-C30评分、IL-4、IL-6、IL-33、ST2水平;低于对照组(P<0.05);治疗后2个月观察组患者血清TNF-α、IFN-γ水平高于对照组,两组患者并发症发生率比较,差异无统计学意义(P>0.05)。结论:^(125)I粒子植入辅助治疗晚期肝癌患者效果显著,可调节血清IL-33、ST2水平,促使Th1/Th2平衡,降低肿瘤标志物水平,提高患者生活质量,且安全性较高。Objective:To explore the changes of interleukin-33(IL-33),cancer suppressor gene 2(ST2),helper T cell 1(Th1)/helper T cell 2(Th2)after^(125)I seed implantation in adjuvant treatment of advanced liver cancer.Methods:A prospective study was conducted on 94 patients with advanced liver cancer admitted to our hospital from July 2019 to April 2021.According to the random number table method,they were divided into an observation group and a control group at a ratio of 1∶1,with 47 cases in each group.The control group was treated with hepatic artery chemotherapy and embolization(TACE),and the observation group was treated with^(125)I seed implantation on the basis of the control group.The efficacy of the two groups,the level of tumor markers[carbohydrate antigen 19-9(CA19-9),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),α-L-fucoidum Glycosidase(AFU)],Quality of Life Core Scale(QLQ-C30)score,Th1[Tumor Necrosis Factor-α(TNF-α),Interferon-γ(IFN-γ)],Th2[Interleukin-4(IL-4),Interleukin-6(IL-6)]related cytokine levels,serum IL-33,ST2 levels before treatment and 2 months after treatment and complication rate were compared between the two groups.Results:The disease control rate of the observation group was 74.47%higher than that of the control group 51.06%(P<0.05);Serum levels of CA19-9,AFP,CEA and AFU in the observation group were lower than those in the control group 2 months after treatment(P<0.05);Two months after treatment,the QLQ-C30 score of the observation group was lower than that of the control group(P<0.05);Two months after treatment,the serum TNF-αand IFN-γlevels of the observation group were higher than those of the control group,and the levels of IL-4,IL-6,IL-33,and ST2 were lower than those of the control group(P<0.05);There was no statistically significant difference in the incidence of complications between the two groups(P>0.05).Conclusion:^(125)I seed implantation is effective in adjuvant treatment of patients with advanced liver cancer.It can adjust serum IL-33 and ST2 levels,promote Th1/Th2

关 键 词：^(125)I粒子植入 晚期肝癌 肝动脉化学治疗栓塞术 肿瘤标志物 癌性抑制基因2 

分 类 号：R735.7[医药卫生—肿瘤]